Tyr333

Site Information
VEDySLLyQ______ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449699

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Disease tissue studied:	leukemia ( 2 ) , chronic myelogenous leukemia ( 2 )
Relevant cell line - cell type - tissue:	32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 1 ) , BaF3 ('B lymphocyte, precursor') ( 2 )

References
1	Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39 19854140 Curated Info
2	Goss V (2003) CST Curation Set: 35; Year: 2003; Biosample/Treatment: cell line, BaF3/pervanadate &'\|\|' Flt3 ligand; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info

References

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140 Curated Info

Goss V (2003) CST Curation Set: 35; Year: 2003; Biosample/Treatment: cell line, BaF3/pervanadate &'||' Flt3 ligand; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info